Advertisement
GSK vs NVS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a StrongBuy and NVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 2 green, 3 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- GSK’s TA Score: 4 bullish, 4 bearish.
- NVS’s TA Score: 6 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +3.63% price change this week, while NVS (@Pharmaceuticals: Major) price change was +2.46% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.85%. For the same industry, the average monthly price growth was +3.30%, and the average quarterly price growth was +17.38%.
Reported Earning Dates
GSK is expected to report earnings on Feb 04, 2026.
NVS is expected to report earnings on Feb 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | NVS | GSK / NVS | |
| Capitalization | 95B | 250B | 38% |
| EBITDA | 10.8B | 22.9B | 47% |
| Gain YTD | 48.086 | 38.872 | 124% |
| P/E Ratio | 13.78 | 17.84 | 77% |
| Revenue | 32.2B | 56.4B | 57% |
| Total Cash | N/A | 9.75B | - |
| Total Debt | N/A | 32B | - |
GSK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 35 | 11 | |
SMR RATING 1..100 | 25 | 28 | |
PRICE GROWTH RATING 1..100 | 41 | 48 | |
P/E GROWTH RATING 1..100 | 87 | 43 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (8) in the Pharmaceuticals Major industry is in the same range as NVS (13). This means that GSK’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is in the same range as GSK (35). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.
GSK's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as NVS (28). This means that GSK’s stock grew similarly to NVS’s over the last 12 months.
GSK's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as NVS (48). This means that GSK’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (87). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | NVS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | 2 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 46% |
| MACD ODDS (%) | 2 days ago 42% | 2 days ago 55% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 48% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 44% |
| Advances ODDS (%) | 2 days ago 60% | 2 days ago 48% |
| Declines ODDS (%) | 8 days ago 50% | 8 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 44% | 2 days ago 45% |
| Aroon ODDS (%) | 2 days ago 49% | 2 days ago 35% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHF | 23.90 | 0.27 | +1.14% |
| Schwab International Equity ETF™ | |||
| DVND | 35.15 | 0.25 | +0.72% |
| Touchstone Dividend Select ETF | |||
| FTCE | 24.58 | 0.11 | +0.44% |
| First Trust New Cstrcts Cr Erns Ldrs ETF | |||
| PCN | 12.75 | 0.05 | +0.39% |
| PIMCO Corporate & Income Strategy Fund | |||
| HYZD | 22.45 | 0.06 | +0.25% |
| WisdomTree Interest Rt Hdg Hi Yld Bd ETF | |||
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.